Filing Flows › Cryoport (CYRX) › Q2 2026 › vs Q2 2025
Cryoport (CYRX) Q2 2026 vs Q2 2025 (year over year)
Cryoport's revenue rose $3.5M (+8%) from $45.5M in Q2 2025 to $49.0M in Q2 2026. The biggest changes: Service +$3.6M (+15%); Product −$83K (-0.4%).
Cryoport, Q2 2026: revenue $49.0M (+8% year over year), operating margin -20.5%, net loss $8.3M, operating cash flow $1.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| BioLogistics Solutions | $22.4M | $19.9M | $2.5M | +13% |
| BioStorage/BioServices | $5.6M | $4.5M | $1.1M | +25% |
| Service | $28.0M | $24.4M | $3.6M | +15% |
| Product | $21.0M | $21.1M | −$83K | -0.4% |
| Revenue | $49.0M | $45.5M | $3.5M | +8% |
| Other income, net | $2.3M | $119M | −$117M | -98% |
| Net loss | $8.3M | −$109M | $117M | — |
| Costs & expenses | $59.5M | $164M | −$105M | -64% |
| Operating costs | $59.0M | $55.1M | $3.9M | +7% |
| Income tax | $505K | $274K | $231K | +84% |
| Cost of revenue | $26.1M | $24.1M | $2.1M | +9% |
| Research & development | $4.9M | $4.1M | $734K | +18% |
| SG&A | $28.0M | $26.9M | $1.1M | +4% |
| Operating cash sources | $9.4M | −$116M | $126M | — |
| Depreciation & amortization | $6.6M | $7.3M | −$707K | -10% |
| Share-based compensation | $2.4M | $2.0M | $357K | +17% |
| Working capital & other | $395K | −$126M | $126M | — |
| Net loss absorbed | $8.3M | −$109M | $117M | — |
| Operating cash flow | $1.1M | −$7.3M | $8.5M | — |
| Capital expenditures | $9.1M | $4.4M | $4.8M | +109% |
| Negative free cash flow (OCF − capex) | $8.0M | $11.7M | −$3.7M | -32% |
Questions
How much did Cryoport's revenue grow year over year in Q2 2026?
Cryoport's revenue rose $3.5M (+8%) from $45.5M in Q2 2025 to $49.0M in Q2 2026.
What drove Cryoport's revenue change in Q2 2026?
Service +$3.6M (+15%); Product −$83K (-0.4%).